Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms

Yong Hyun Park, Tae Hyo Kim, Seung Wook Lee, Byungha Chung, Jin Seon Cho, Ji Youl Lee

Research output: Contribution to journalArticle

Abstract

Objectives: We aimed to examine the treatment patterns, and patient-reported outcomes (PROs) in benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. Methods: Seven hundred and forty seven patients were included in this prospective observational study. The primary endpoint was to describe the medical treatment patterns for BPH patients with OAB symptoms. The secondary endpoint was to determine the PROs of these patients. Clinical outcome was assessed using International prostate symptom score (IPSS), and PROs were measured using BPH-Related QoL Questionnaire Korea 1 (BPH QoL K1) and Euroqol-5 Dimension (EQ-5D). Results: When starting the study, 391 patients (52.3%) received α-blocker monotherapy, whereas 356 (47.7%) received combination therapy with anticholinergics. Of the 369 patients who completed the 6-month treatment, 139 patients (37.7%) still received α-blocker monotherapy, 122 (33.1%) still received combination therapy with anticholinergics, and 108 (29.3%) received subsequent anticholinergics in addition to α-blocker. When the patients were stratified, storage subscore was higher (9.5 vs. 8.8, P = 0.034) and voiding subscore (9.7 vs. 11.6, P = 0.001) was lower in patients with anticholinergics than those without it. Although all treatment groups reported a significant improvement from baseline, no significant between-group differences in changes in IPSS, EQ-5D and BPH QoL K1 was found. Conclusions: About one-third of patients received α-blocker monotherapy, one-third received combination therapy with anticholinergics, and another one-third received subsequent anticholinergics in addition to α-blocker. Storage subscore was higher in patients with anticholinergics than those without it, but vice-versa for voiding subscore. Similar improvement on clinical outcomes and PROs was observed in all treatment groups.

Original languageEnglish
Pages (from-to)75-81
Number of pages7
JournalLUTS: Lower Urinary Tract Symptoms
Volume9
Issue number2
DOIs
Publication statusPublished - 2017 May 1

Fingerprint

Overactive Urinary Bladder
Prostatic Hyperplasia
Cholinergic Antagonists
Therapeutics
Prostate
Patient Reported Outcome Measures
Korea
Observational Studies
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Neurology
  • Urology

Cite this

Park, Yong Hyun ; Kim, Tae Hyo ; Lee, Seung Wook ; Chung, Byungha ; Cho, Jin Seon ; Lee, Ji Youl. / Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. In: LUTS: Lower Urinary Tract Symptoms. 2017 ; Vol. 9, No. 2. pp. 75-81.
@article{a1b11fb400ee45de8600c6a5528c0a38,
title = "Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms",
abstract = "Objectives: We aimed to examine the treatment patterns, and patient-reported outcomes (PROs) in benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. Methods: Seven hundred and forty seven patients were included in this prospective observational study. The primary endpoint was to describe the medical treatment patterns for BPH patients with OAB symptoms. The secondary endpoint was to determine the PROs of these patients. Clinical outcome was assessed using International prostate symptom score (IPSS), and PROs were measured using BPH-Related QoL Questionnaire Korea 1 (BPH QoL K1) and Euroqol-5 Dimension (EQ-5D). Results: When starting the study, 391 patients (52.3{\%}) received α-blocker monotherapy, whereas 356 (47.7{\%}) received combination therapy with anticholinergics. Of the 369 patients who completed the 6-month treatment, 139 patients (37.7{\%}) still received α-blocker monotherapy, 122 (33.1{\%}) still received combination therapy with anticholinergics, and 108 (29.3{\%}) received subsequent anticholinergics in addition to α-blocker. When the patients were stratified, storage subscore was higher (9.5 vs. 8.8, P = 0.034) and voiding subscore (9.7 vs. 11.6, P = 0.001) was lower in patients with anticholinergics than those without it. Although all treatment groups reported a significant improvement from baseline, no significant between-group differences in changes in IPSS, EQ-5D and BPH QoL K1 was found. Conclusions: About one-third of patients received α-blocker monotherapy, one-third received combination therapy with anticholinergics, and another one-third received subsequent anticholinergics in addition to α-blocker. Storage subscore was higher in patients with anticholinergics than those without it, but vice-versa for voiding subscore. Similar improvement on clinical outcomes and PROs was observed in all treatment groups.",
author = "Park, {Yong Hyun} and Kim, {Tae Hyo} and Lee, {Seung Wook} and Byungha Chung and Cho, {Jin Seon} and Lee, {Ji Youl}",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/luts.12112",
language = "English",
volume = "9",
pages = "75--81",
journal = "LUTS: Lower Urinary Tract Symptoms",
issn = "1757-5664",
publisher = "Wiley Blackwell",
number = "2",

}

Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms. / Park, Yong Hyun; Kim, Tae Hyo; Lee, Seung Wook; Chung, Byungha; Cho, Jin Seon; Lee, Ji Youl.

In: LUTS: Lower Urinary Tract Symptoms, Vol. 9, No. 2, 01.05.2017, p. 75-81.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment Patterns and Patient Reported Outcomes in Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms

AU - Park, Yong Hyun

AU - Kim, Tae Hyo

AU - Lee, Seung Wook

AU - Chung, Byungha

AU - Cho, Jin Seon

AU - Lee, Ji Youl

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objectives: We aimed to examine the treatment patterns, and patient-reported outcomes (PROs) in benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. Methods: Seven hundred and forty seven patients were included in this prospective observational study. The primary endpoint was to describe the medical treatment patterns for BPH patients with OAB symptoms. The secondary endpoint was to determine the PROs of these patients. Clinical outcome was assessed using International prostate symptom score (IPSS), and PROs were measured using BPH-Related QoL Questionnaire Korea 1 (BPH QoL K1) and Euroqol-5 Dimension (EQ-5D). Results: When starting the study, 391 patients (52.3%) received α-blocker monotherapy, whereas 356 (47.7%) received combination therapy with anticholinergics. Of the 369 patients who completed the 6-month treatment, 139 patients (37.7%) still received α-blocker monotherapy, 122 (33.1%) still received combination therapy with anticholinergics, and 108 (29.3%) received subsequent anticholinergics in addition to α-blocker. When the patients were stratified, storage subscore was higher (9.5 vs. 8.8, P = 0.034) and voiding subscore (9.7 vs. 11.6, P = 0.001) was lower in patients with anticholinergics than those without it. Although all treatment groups reported a significant improvement from baseline, no significant between-group differences in changes in IPSS, EQ-5D and BPH QoL K1 was found. Conclusions: About one-third of patients received α-blocker monotherapy, one-third received combination therapy with anticholinergics, and another one-third received subsequent anticholinergics in addition to α-blocker. Storage subscore was higher in patients with anticholinergics than those without it, but vice-versa for voiding subscore. Similar improvement on clinical outcomes and PROs was observed in all treatment groups.

AB - Objectives: We aimed to examine the treatment patterns, and patient-reported outcomes (PROs) in benign prostatic hyperplasia (BPH) patients with overactive bladder (OAB) symptoms. Methods: Seven hundred and forty seven patients were included in this prospective observational study. The primary endpoint was to describe the medical treatment patterns for BPH patients with OAB symptoms. The secondary endpoint was to determine the PROs of these patients. Clinical outcome was assessed using International prostate symptom score (IPSS), and PROs were measured using BPH-Related QoL Questionnaire Korea 1 (BPH QoL K1) and Euroqol-5 Dimension (EQ-5D). Results: When starting the study, 391 patients (52.3%) received α-blocker monotherapy, whereas 356 (47.7%) received combination therapy with anticholinergics. Of the 369 patients who completed the 6-month treatment, 139 patients (37.7%) still received α-blocker monotherapy, 122 (33.1%) still received combination therapy with anticholinergics, and 108 (29.3%) received subsequent anticholinergics in addition to α-blocker. When the patients were stratified, storage subscore was higher (9.5 vs. 8.8, P = 0.034) and voiding subscore (9.7 vs. 11.6, P = 0.001) was lower in patients with anticholinergics than those without it. Although all treatment groups reported a significant improvement from baseline, no significant between-group differences in changes in IPSS, EQ-5D and BPH QoL K1 was found. Conclusions: About one-third of patients received α-blocker monotherapy, one-third received combination therapy with anticholinergics, and another one-third received subsequent anticholinergics in addition to α-blocker. Storage subscore was higher in patients with anticholinergics than those without it, but vice-versa for voiding subscore. Similar improvement on clinical outcomes and PROs was observed in all treatment groups.

UR - http://www.scopus.com/inward/record.url?scp=84944128633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944128633&partnerID=8YFLogxK

U2 - 10.1111/luts.12112

DO - 10.1111/luts.12112

M3 - Article

VL - 9

SP - 75

EP - 81

JO - LUTS: Lower Urinary Tract Symptoms

JF - LUTS: Lower Urinary Tract Symptoms

SN - 1757-5664

IS - 2

ER -